Kazia Therapeutics Files Form 6-K
Ticker: KZIA · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1075880
Sentiment: neutral
Topics: foreign-issuer, regulatory-filing, pharmaceutical
TL;DR
Kazia Therapeutics (KZA) filed a 6-K, standard foreign issuer report.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 13, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations company. This filing is a report of a foreign private issuer.
Why It Matters
This filing indicates Kazia Therapeutics is a foreign private issuer reporting under US securities laws, which is standard for companies with US listings but operations primarily abroad.
Risk Assessment
Risk Level: low — A Form 6-K is a routine filing for foreign private issuers and does not typically contain material non-public information that would impact risk.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- September 13, 2024 (date) — Filing date
- Sydney NSW (location) — Company headquarters
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of a foreign private issuer required to be filed with the SEC to provide information that the issuer has made or is required to make public pursuant to the laws of its home country or stock exchange, or has submitted or is required to submit to its security holders.
When was Kazia Therapeutics Limited previously known by another name?
Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change in 19981228.
Where is Kazia Therapeutics Limited's principal executive office located?
The principal executive office of Kazia Therapeutics Limited is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file annual reports under Form 20-F or Form 40-F?
Kazia Therapeutics Limited indicates it files annual reports under Form 20-F.
What is the SIC code for Kazia Therapeutics Limited?
The Standard Industrial Classification (SIC) code for Kazia Therapeutics Limited is Pharmaceutical Preparations [2834].
Filing Stats: 296 words · 1 min read · ~1 pages · Grade level 13.7 · Accepted 2024-09-13 09:06:55
Filing Documents
- d840862d6k.htm (6-K) — 9KB
- d840862dex991.htm (EX-99.1) — 12KB
- g840862dsp4.jpg (GRAPHIC) — 5KB
- 0001193125-24-218497.txt ( ) — 29KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On September 12, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Executes Licensing Agreement with QIMR Berghofer. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the respective quotes of Dr. John Friend, Chief Executive Officer of the Company, and Professor Fabienne Mackay, Director and Chief Executive Officer of QIMR Berghofer, contained in Exhibit 99.1, into the Companys registration statements on Form F-3 (File No. 333-276091 and 333-281937). EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated September 12, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 13 September 2024